Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 269, Issue 1-2, Pages 87-89Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2014.02.004
Keywords
Multiple sclerosis; Glia; Cerebrospinal fluid; Biomarker; Immunotherapy
Categories
Funding
- Swedish Research Council [K2009-65X-15424-05-3, K2011-X-20401-05-6]
- Swedish Federal Government under the LUA/ALF agreement
- Arosenius Foundation
- Wilhelm and Martina Lundgren Science Foundation
- Knut and Alice Wallenberg Foundation
- Swedish Society of the Neurologically Disabled
- Research Foundation of the Multiple Sclerosis Society of Gothenburg
- Edit Jacobson Foundation
- BiogenIdec
Ask authors/readers for more resources
The role of glial cells during different phases of multiple sclerosis (MS) is unclear. To monitor glial activation we analyzed the biomarkers YKL-40 and sCD14 in cerebrospinal fluid (CSF) from MS patients during different disease phases and in response to immunosuppressive treatment. CSF levels of YKL-40 were increased in MS during relapse, remission and secondary progression compared with healthy controls. Furthermore, YKL-40 levels in CSF decreased by mitoxantrone and natalizumab treatment. No differences were observed in CSF levels of sCD14. Thus, we can infer that glial activation is present in all MS phases and decreases by immunosuppressive treatment. 2014 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available